Published in AIDS Res Ther on June 03, 2010
Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis (2012) 2.37
HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nat Rev Neurol (2016) 1.71
Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS (2013) 1.71
Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology (2015) 1.66
Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS One (2012) 1.55
Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease. Int J Geriatr Psychiatry (2012) 1.47
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr (2012) 1.44
Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine (2015) 1.36
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15
HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study. PLoS One (2013) 1.11
New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. Curr HIV/AIDS Rep (2012) 1.08
Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Curr HIV/AIDS Rep (2015) 1.03
Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young children. PLoS Pathog (2012) 1.01
Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol (2013) 0.98
Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS (2014) 0.98
CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation. J Neuroinflammation (2014) 0.95
Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation (2013) 0.95
Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection. J Neuroinflammation (2014) 0.91
Role of HIV in amyloid metabolism. J Neuroimmune Pharmacol (2014) 0.90
Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy. Scand J Infect Dis (2012) 0.89
Evolving character of chronic central nervous system HIV infection. Semin Neurol (2014) 0.89
Neopterin in Diagnosis and Monitoring of Infectious Diseases. J Biomark (2013) 0.89
Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection. Neurology (2014) 0.88
Role of neuroimaging in HIV-associated neurocognitive disorders. Semin Neurol (2014) 0.88
Paving the path to HIV neurotherapy: Predicting SIV CNS disease. Eur J Pharmacol (2015) 0.88
The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clin Proteomics (2012) 0.88
Neuroimaging of HIV-associated neurocognitive disorders (HAND). Curr Opin HIV AIDS (2014) 0.88
Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr (2015) 0.87
Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study. AIDS Res Ther (2011) 0.86
Cerebral white matter integrity during primary HIV infection. AIDS (2015) 0.85
Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. J Clin Pharmacol (2014) 0.85
Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease. J Infect Dis (2014) 0.84
A biological perspective of CSF lipids as surrogate markers for cognitive status in HIV. J Neuroimmune Pharmacol (2013) 0.82
Markers for sepsis diagnosis in the forensic setting: state of the art. Croat Med J (2014) 0.82
Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease. J Neurovirol (2014) 0.82
Immune activation in the central nervous system throughout the course of HIV infection. Curr Opin HIV AIDS (2016) 0.82
CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. J Neurovirol (2015) 0.81
Cerebrospinal fluid neopterin analysis in neuropediatric patients: establishment of a new cut off-value for the identification of inflammatory-immune mediated processes. PLoS One (2013) 0.81
Elevated cerebrospinal fluid neopterin concentration is associated with disease severity in acute Puumala hantavirus infection. Clin Dev Immunol (2013) 0.80
Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation. J Acquir Immune Defic Syndr (2014) 0.80
Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis (2013) 0.80
Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naïve HIV-infected Thais. J Neuroimmunol (2015) 0.79
Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. Open Forum Infect Dis (2015) 0.79
Postmortem chemistry update part II. Int J Legal Med (2011) 0.78
Calpain-mediated degradation of MDMx/MDM4 contributes to HIV-induced neuronal damage. Mol Cell Neurosci (2013) 0.78
Probiotics Differently Affect Gut-Associated Lymphoid Tissue Indolamine-2,3-Dioxygenase mRNA and Cerebrospinal Fluid Neopterin Levels in Antiretroviral-Treated HIV-1 Infected Patients: A Pilot Study. Int J Mol Sci (2016) 0.77
Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS One (2016) 0.77
Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study. BMC Infect Dis (2016) 0.76
Blood-CSF barrier and compartmentalization of CNS cellular immune response in HIV infection. J Neuroimmunol (2016) 0.76
Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity. J Neuroinflammation (2017) 0.75
Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected Individuals. Int J Tryptophan Res (2016) 0.75
Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. J Neurovirol (2016) 0.75
Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection. PLoS One (2016) 0.75
Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
Highly efficient SERS-based detection of cerebrospinal fluid neopterin as a diagnostic marker of bacterial infection. Anal Bioanal Chem (2016) 0.75
Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens. J Clin Pharmacol (2015) 0.75
Impact of antiretroviral therapy on HIV-related brain injury. Clin Infect Dis (2011) 0.75
High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid. Open Forum Infect Dis (2017) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The AIDS dementia complex: II. Neuropathology. Ann Neurol (1986) 5.61
The AIDS dementia complex: I. Clinical features. Ann Neurol (1986) 5.22
Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol (1997) 2.92
The AIDS dementia complex. J Infect Dis (1988) 2.77
Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci (2002) 2.39
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis (2006) 2.36
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis (2007) 1.92
Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis (1997) 1.90
Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis (2009) 1.82
Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev (2009) 1.73
Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol (2008) 1.70
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol (2005) 1.68
Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem (1989) 1.66
Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog (2009) 1.66
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr (1999) 1.53
Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. J Thromb Haemost (2006) 1.52
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr (2002) 1.46
Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci (1987) 1.42
Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr Drug Metab (2002) 1.40
Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr (1990) 1.39
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res (2003) 1.32
Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis (2005) 1.25
Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis (1993) 1.17
Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol (2001) 1.17
Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis (1996) 1.15
Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol (1990) 1.14
Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett (1993) 1.14
Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS (1989) 1.08
Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler (1989) 1.08
Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS (2002) 1.04
Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol (1999) 1.01
Commercial enzyme-linked immunosorbent assay for neopterin detection in blood donations compared with RIA and HPLC. Clin Chem (1994) 0.97
Neopterin activates transcription factor nuclear factor-kappa B in vascular smooth muscle cells. FEBS Lett (1996) 0.97
Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. Scand J Infect Dis (1994) 0.95
Peroxide and pteridine: a hypothesis on the regulation of macrophage antimicrobial activity by interferon gamma. Interferon (1986) 0.94
Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS (1989) 0.91
Neopterin-induced tumor necrosis factor-alpha synthesis in vascular smooth muscle cells in vitro. Int Arch Allergy Immunol (1998) 0.90
Atorvastatin suppresses interferon-gamma -induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin Exp Immunol (2003) 0.88
Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells. Neurosci Lett (2008) 0.88
Comparison of HIV-1 pol and env sequences of blood, CSF, brain and spleen isolates collected ante-mortem and post-mortem. Acta Neurol Scand (2008) 0.87
Neopterin-induced expression of intercellular adhesion molecule-1 (ICAM-1) in type II-like alveolar epithelial cells. Clin Exp Immunol (1999) 0.85
Neurological efficacy of stavudine, zidovudine, and lamivudine. Lancet (1998) 0.85
Kynurenine metabolites of tryptophan: implications for neurologic diseases. Neurology (1990) 0.80
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46
Neurological complications of HIV infection. Lancet Neurol (2005) 3.25
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med (2007) 2.88
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (2003) 2.69
HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood (2006) 2.58
Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol (2003) 2.50
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis (2012) 2.37
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis (2006) 2.36
Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta (2005) 2.29
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res (2006) 2.26
Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry (2011) 2.23
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry (2003) 2.05
Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis (2011) 1.96
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.94
Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia (2005) 1.93
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis (2007) 1.92
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem (2002) 1.89
Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis (2009) 1.82
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials (2010) 1.75
Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol (2003) 1.75
A protocol-driven model for the rapid initiation of stroke thrombolysis in the emergency department. Med J Aust (2007) 1.74
Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev (2009) 1.73
HIV-1 infection and cognitive impairment in the cART era: a review. AIDS (2011) 1.72
Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol (2009) 1.70
Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol (2003) 1.70
Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol (2008) 1.69
Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog (2009) 1.66
Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65
Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol (2004) 1.59
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis (2011) 1.59
Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem (2009) 1.57
Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis (2008) 1.56
HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS (2010) 1.56
Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology (2006) 1.56
The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis (2011) 1.54
Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol (2011) 1.51
Cerebrospinal fluid neopterin is brain-derived and not associated with blood-CSF barrier dysfunction in non-inflammatory affective and schizophrenic spectrum disorders. J Psychiatr Res (2013) 1.50
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis (2005) 1.47
Urinary neopterin concentrations in patients with Balkan endemic nephropathy (BEN). Kidney Int (2003) 1.47
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood (2006) 1.45
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Characterization of the kynurenine pathway in human neurons. J Neurosci (2007) 1.44
[Soluble interleukin-2 and tumor necrosis factor receptor in liver cirrhosis. Relationship with clinical severity and prognosis]. Med Clin (Barc) (2004) 1.43
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
The relationship between alcohol intake and cellular immune activity in systemic lupus erythematosus may change from inhibitory to stimulatory within 2 months of study: findings from an integrative single-case study. Clin Rheumatol (2009) 1.41
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS (2009) 1.40
Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis (2004) 1.40
Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem (2004) 1.37
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection. J Virol (2007) 1.32
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis (2011) 1.32
An international external quality assessment of nucleic acid amplification of herpes simplex virus. J Clin Virol (2003) 1.30
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer (2008) 1.30